Hospice and Palliative Medicine

A patient approved for medical aid in dying has to choose among compounded multi-drug regimens built to replace a barbiturate that no longer exists on the market — and the choice trades a slower, more familiar drug combination against a faster one with a thinner safety record.

A dying man's breathlessness and agitation have stopped responding to standard comfort measures, and the question is no longer whether to sedate him but which drug gets there reliably in someone whose body has spent a decade building tolerance to the first, most obvious choice.

A hospice patient's terminal delirium is frightening her family more than it seems to be distressing her, and the trial that supposedly settled how to treat it found the standard drugs made people worse — a finding the team has to decide whether it actually applies to this patient's more severe presentation.

A dying man's liver has stopped reliably clearing the opioid that has kept him comfortable for weeks, and the choice of what replaces it turns on which drug's metabolism actually depends on the organ that's failing — a clearance question, not the cancer-specific nutrition-and-hydration question this same discipline asks elsewhere.

A severely cachectic hospice patient's pain has crept back despite an unchanged fentanyl patch dose, and the reflexive answer — opioid tolerance — misses a simpler, absorption-driven explanation sitting in what forty-six pounds of wasting has done to the skin the patch actually delivers through.

A dying woman's air hunger has stopped responding to everything disease-directed therapy can offer, and her husband wants the anti-anxiety drug started first because her breathing looks like panic — but the evidence for what actually helps points the other way.

A man newly enrolled in hospice is still taking fourteen daily medications from a life expectancy that no longer applies to him, and the team has to decide, drug by drug, which ones are protecting him from something real and which are protecting him from nothing he'll live long enough to need protecting from.

A grandfather enrolled in home hospice for end-stage heart failure is fading despite a guideline-perfect medication regimen, and his family is asking about a continuous inotrope infusion they read about online — a drug with real arrhythmia risk that the team still has to weigh honestly against what it might actually buy him.

A woman with advanced dementia has nearly stopped eating, and her husband of fifty-nine years wants a feeding tube placed because the alternative feels to him like giving up — but the evidence on what a feeding tube actually does in this specific disease says the choice he's hoping for doesn't deliver the outcome he's picturing.

An actively dying man's audible secretions are distressing everyone in the room except, as far as anyone can tell, him — and the one randomized trial supporting the drug his family is asking for tested it as prevention in patients who had not yet started rattling — which is not the situation in front of them.

A man dying of end-stage COPD wants to try cannabis for his appetite and anxiety before hospice regulations and his own decline make that impossible, and the team has to separate what patients and families genuinely believe about cannabinoids at the end of life from what the actual comparative trial evidence supports.

A woman facing a terminal cancer diagnosis has read about psilocybin-assisted therapy for exactly the death anxiety she's living through, and the honest answer isn't whether the treatment works — the trial evidence is genuinely strong — it's that federal scheduling and her own state's law mean the drug she's reading about isn't actually available to her the ordinary way.

A man with worsening Parkinson's disease is nowhere near end of life by any conventional marker, and his neurologist has to decide whether the randomized evidence for early palliative-care integration in this exact disease applies to a patient this far from what palliative care has traditionally meant.

A man on his fourth line of therapy for relapsed multiple myeloma is still actively fighting his disease, and his oncologist has to decide whether asking a palliative care team to join now, rather than after treatment options run out, sends the message he fears it will — or corrects a documented pattern where patients like him get referred later than almost anyone else with cancer.